Payment overview · 2025
General Payments
$836.18
53 reported records · 16 companies
Healthcare provider profile · identity verified
Thomas Dwayne Johnson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JAMESTOWN, KY · NPI 1821096421
Verified facts
What the public records show
CMS Open Payments records show Thomas Dwayne Johnson, MD received $836.18 in general payments during 2025 across 53 reported records.
Medtronic, Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$170.77 | 20.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $152.68 | 18.3% | 21 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $99.12 | 11.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $96.80 | 11.6% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.91 | 7.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.18 | 5.2% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $35.29 | 4.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.79 | 4.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.90 | 3.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.71 | 2.5% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.88 | 2.4% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.08 | 1.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.82 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.44 | 1.7% | 4 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $14.29 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.52 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $836.18 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $170.77 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $122.82 | 19 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $99.12 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.81 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.29 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.99 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $43.18 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.79 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $32.90 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.76 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.86 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.86 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.86 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.44 | 4 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 99 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
81 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
99 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 583 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 574 | 153 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 521 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 414 | 115 |
| Lisinopril | Lisinopril | 404 | 117 |
| Omeprazole | Omeprazole | 285 | 76 |
| Alprazolam | Alprazolam | 284 | 40 |
| Gabapentin | Gabapentin | 271 | 52 |
| Losartan Potassium | Losartan Potassium | 260 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 221 | 72 |
| Furosemide | Furosemide | 210 | 67 |
| Methylprednisolone | Methylprednisolone | 210 | 155 |
| Simvastatin | Simvastatin | 198 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 181 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 59 |
| Glimepiride | Glimepiride | 171 | 49 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 163 | 26 |
| Potassium Chloride | Potassium Chloride | 157 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 48 |
| Metformin Hcl Er | Metformin Hcl | 149 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 149 | 40 |
| Metformin Hcl | Metformin Hcl | 139 | 43 |
| Trazodone Hcl | Trazodone Hcl | 139 | 39 |
| Montelukast Sodium | Montelukast Sodium | 133 | 37 |
| Carvedilol | Carvedilol | 127 | 37 |
| Meloxicam | Meloxicam | 126 | 44 |
| Clonazepam | Clonazepam | 123 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 38 |
| Sertraline Hcl | Sertraline Hcl | 121 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 32 |
| Diazepam | Diazepam | 111 | 16 |
| Azithromycin | Azithromycin | 102 | 81 |
| Allopurinol | Allopurinol | 99 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 99 | 24 |
| Tramadol Hcl | Tramadol Hcl | 98 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 30 |
| Alendronate Sodium | Alendronate Sodium | 86 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 24 |
| Synthroid | Levothyroxine Sodium | 81 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 20 |
| Pregabalin | Pregabalin | 77 | 12 |
| Buspirone Hcl | Buspirone Hcl | 75 | 22 |
| Eliquis | Apixaban | 75 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 19 |
| Famotidine | Famotidine | 73 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 21 |
| Prednisone | Prednisone | 63 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 17 |
| Ibuprofen | Ibuprofen | 56 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | 15 |
| Amoxicillin | Amoxicillin | 54 | 43 |
| Atenolol | Atenolol | 54 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 53 | 12 |
| Fenofibrate | Fenofibrate | 50 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 42 |
| Doxepin Hcl | Doxepin Hcl | 48 | suppressed |
| Ezetimibe | Ezetimibe | 48 | 17 |
| Ondansetron Odt | Ondansetron | 48 | 11 |
| Jardiance | Empagliflozin | 47 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 12 |
| Mounjaro | Tirzepatide | 45 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 32 |
| Baclofen | Baclofen | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 13 |
| Valsartan | Valsartan | 41 | suppressed |
| Nystatin | Nystatin | 40 | 19 |
| Mirtazapine | Mirtazapine | 38 | 12 |
| Promethazine Hcl | Promethazine Hcl | 38 | 12 |
| Cefdinir | Cefdinir | 37 | 32 |
| Ozempic | Semaglutide | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 12 |
| Cephalexin | Cephalexin | 36 | 21 |
| Vascepa | Icosapent Ethyl | 36 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | 13 |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 19 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | 14 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 17 |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Colchicine | Colchicine | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $836.18 · 53 records | Medtronic, Inc. | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FARXIGA, Heplisav-B, JATENZO, NEXLETOL, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SYMPLICITY G3, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, XYOSTED, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error